48-Hour test may predict who benefits from PKU drug
NCT ID NCT07255599
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a 48-hour BH4 loading test can predict which people with phenylketonuria (PKU) will respond to treatment. Twenty participants receive BH4 and have their blood phenylalanine levels measured over two days. The goal is to link test results with each person's genetic makeup to improve personalized care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
- What this could lead to
- If successful, this could help doctors quickly identify which PKU patients benefit from BH4 therapy, personalizing treatment and avoiding unnecessary medication.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply to all PKU patients. The 48-hour test may not reliably predict long-term response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA (PKU) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag Faculty of Medicine
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden weight problem: PKU adults face higher obesity risk, scientists investigate why
- New oral drug aims to tame PKU's toxic protein buildup
- Experimental enzyme injection aims to tame PKU's toxic amino acid
- Tiny tablets could make PKU management easier for patients
- New PKU drug JNT-517 moves to Long-Term safety trial
- New pill for PKU shows promise in small teen trial